Evidence map›Paper›PMID 37255050›Full record

ArticleThe Laryngoscope2024

Transoral Surgery in HPV-Positive Oropharyngeal Carcinoma: Oncologic Outcomes in the Veterans Affairs System.

Farhoud Faraji, Abhishek Kumar, Rohith Voora, Shady I Soliman, Daniel Cherry, P Travis Courtney, Andrey Finegersh, Theresa Guo, Ezra Cohen, Joseph A Califano and 3 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Laryngoscope, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
1.0field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it, 3 citations in OpenAlex.

  1. Pooled it
  2. Patient-reported outcomes in oropharyngeal cancer: comparing two cohorts with different treatment protocols.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 1 country.

Farhoud FarajiDepartment of Otolaryngology-Head and Neck Surgery, University of California San Diego Health, San Diego, California, USA.ORCID 0000-0001-5078-813X
Abhishek KumarDepartment of Radiation Medicine and Applied Sciences, University of California San Diego Health, La Jolla, California, USA.
Rohith VooraDepartment of Otolaryngology-Head and Neck Surgery, University of California San Diego Health, San Diego, California, USA.
Shady I SolimanDepartment of Otolaryngology-Head and Neck Surgery, University of California San Diego Health, San Diego, California, USA.ORCID 0000-0001-5291-6940
Daniel CherryDepartment of Radiation Medicine and Applied Sciences, University of California San Diego Health, La Jolla, California, USA.
P Travis CourtneyDepartment of Radiation Medicine and Applied Sciences, University of California San Diego Health, La Jolla, California, USA.
Andrey FinegershDepartment of Otolaryngology-Head and Neck Surgery, University of California San Diego Health, San Diego, California, USA.
Theresa GuoDepartment of Otolaryngology-Head and Neck Surgery, University of California San Diego Health, San Diego, California, USA.
Ezra CohenMoores Cancer Center, University of California San Diego Health, La Jolla, California, USA.
Joseph A CalifanoDepartment of Otolaryngology-Head and Neck Surgery, University of California San Diego Health, San Diego, California, USA.
Loren MellMoores Cancer Center, University of California San Diego Health, La Jolla, California, USA.
Brent RoseMoores Cancer Center, University of California San Diego Health, La Jolla, California, USA.
Ryan K OroscoDivision of Otolaryngology-Head and Neck Surgery, Department of Surgery, University of New Mexico, Albuquerque, New Mexico, USA.ORCID 0000-0002-7885-4327
University of San Diego · USUniversity of California San Diego · USDuke University · USUniversity of New Mexico · US

Funding

UC San Diego Clinical and Translational Research InstituteUL1TR001442 · NCATS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI FIRESTEIN, GARY S, HOGARTH, MICHAEL · 2015 to 2024
$88.3M
UC San Diego Clinical and Translational Research InstituteKL2TR001444 · NCATS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI DEPP, COLIN A. · 2015 to 2024
$15.4M
UC San Diego Clinical and Translational Research InstituteTL1TR001443 · NCATS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI DEPP, COLIN A. · 2015 to 2019
$3.4M
OTOLARYNGOLOGY TRAINING IN IMMUN., VIROL. &MOLEC. BIOL.T32DC000028 · NIDCD · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI RYAN, ALLEN F. · 1989 to 2020
$2.1M
NCATS NIH HHS KL2 TR001444NCATS NIH HHS TL1 TR001443NCATS NIH HHS UL1 TR001442NIDCD NIH HHS T32 DC000028NIH HHS T32DC000028NIH HHS TL1TR001443
6 · The paper itself

Abstract

objectivesMost transoral robotic surgery (TORS) literature for HPV-positive oropharyngeal squamous cell carcinoma (HPV-OPC) derives from high-volume tertiary-care centers. This study aims to describe long-term recurrence and survival outcomes among Veterans Health Administration patients. MATERIALS AND

methodsUsing the US Veterans Affairs database, we identified patients with HPV-OPC treated with TORS between January 2010 and December 2016. Patients were stratified in risk categories: low (0-1 metastatic nodes, negative margins), intermediate (close margins, 2-4 metastatic nodes, lymphovascular or perineural invasion, pT3-pT4 tumor), or high (positive margins, extranodal extension (ENE), and/or ≥5 metastatic nodes). Primary outcomes included overall survival (OS), disease-specific survival (DSS), and recurrence-free survival (RFS).

resultsThe cohort included 161 patients of which 29 (18%) were low-risk, 45 (28%) intermediate-risk, and 87 (54%) high-risk. ENE was present in 41% of node-positive cases and 24% had positive margins. Median follow-up was 5.6 years (95% CI, 3.0-9.3). The 5-year DSS for low, intermediate, and high-risk groups were: 100%, 90.0% (95% CI, 75.4-96.1%), and 88.7% (95% CI, 78.3-94.2%). Pathologic features associated with poor DSS on univariable analysis included pT3-T4 tumors (HR 3.81, 95% CI, 1.31-11; p = 0.01), ≥5 metastatic nodes (HR 3.41, 95% CI, 1.20-11; p = 0.02), and ENE (HR 3.53, 95% CI, 1.06-12; p = 0.04). Higher 5-year cumulative incidences of recurrence were observed in more advanced tumors (pT3-T4, 33% [95% CI, 14-54%] versus pT1-T2, 13% [95% CI, 8-19%]; p = 0.01).

conclusionsIn this nationwide study, patients with HPV-OPC treated with TORS followed by adjuvant therapy at Veterans Affairs Medical Centers demonstrated favorable survival outcomes comparable to those reported in high-volume academic centers and clinical trials. LEVEL OF EVIDENCE: 4 Laryngoscope, 134:207-214, 2024.

Indexed as

Carcinoma, Squamous CellHead and Neck NeoplasmsOropharyngeal NeoplasmsPapillomavirus InfectionsRobotic Surgical ProceduresVeteransHumansRetrospective StudiesSquamous Cell Carcinoma of Head and NeckHPVoncologic outcomesoropharyngeal carcinomatransoral surgery

Identifiers

PMID37255050
PMCPMC10687307
OpenAlexW4378781333

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.